PALO ALTO, Calif., March 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Barclays Global Healthcare Conference in Miami Beach, FL on Tuesday, March 12 at 1:35 p.m. Eastern Time.
A live audio webcast of the presentation will be available on the "Investor Relations" section of Kodiak's website at http://ir.kodiak.com/ and will be available for replay for a limited time following the event.
About Kodiak Sciences Inc.
Kodiak™ is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our ABC Platform™ merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. In addition to its lead product candidate, KSI-301, a novel anti-VEGF antibody biopolymer conjugate in clinical development for the treatment of age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in Palo Alto, CA. For more information, visit www.kodiak.com.
Advertisement
A live audio webcast of the presentation will be available on the "Investor Relations" section of Kodiak's website at http://ir.kodiak.com/ and will be available for replay for a limited time following the event.
Advertisement
About Kodiak Sciences Inc.
Kodiak™ is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our ABC Platform™ merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. In addition to its lead product candidate, KSI-301, a novel anti-VEGF antibody biopolymer conjugate in clinical development for the treatment of age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in Palo Alto, CA. For more information, visit www.kodiak.com.
View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-barclays-global-healthcare-conference-300808269.html
SOURCE Kodiak Sciences Inc.
